NDAINTRAMUSCULARSOLUTIONPriority Review
Approved
May 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
5/8 — Partial
Priority Review
ATROPEN (atropine) by Medcaptain Medical Technology is cholinergic antagonists [moa]. Approved for neuromuscular blockade reversal, bradycardia, post-operative residual curarization. First approved in 1973.
Drug data last refreshed Yesterday
Mechanism of Action
Cholinergic Antagonists
Pharmacologic Class:
Anticholinergic
Indications (3)
Worked on ATROPEN at Medcaptain Medical Technology? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.